Khayat D, Antoine E, Rixe O, Tourani J M, Vuillemin E, Borel C, Benhammouda A, Thill L, Franks C, Auclerc G
Service d'Oncologie Médicale, Hôpital de la Salpétrière, Paris, France.
Eur J Cancer. 1993;29A Suppl 5:S2-5. doi: 10.1016/0959-8049(93)90616-n.
Optimistic results were obtained in the treatment of 39 patients with surgically incurable metastatic malignant melanoma using a regimen including 2 to 3 monthly induction cycles of cis-diamminedichloroplatinum (CDDP), recombinant interleukin-2 (rIL-2) and interferon alpha-2a (IFN alpha-2a). 33 of 39 patients were pretreated with chemotherapy (dacarbazine and/or fotemustine:31, CDDP:6) and 17 of 39 with IFN alpha-2a. Overall response rate was 54% with 13% achieving a complete response for up to 59+ weeks. Moderate to severe side-effects were reversible on rIL-2 cessation and toxicity was manageable in a routine inpatient setting. These results are especially encouraging as they were seen in previously treated patients, classically low responders, including 3 who were resistant to cisplatin or other platinum complexes. The question remains if this regimen bypasses traditional mechanisms of drug resistance.
采用包括顺二氯二氨铂（CDDP）、重组白细胞介素-2（rIL-2）和干扰素α-2a（IFNα-2a）的方案，每月进行2至3个诱导周期，对39例手术无法治愈的转移性恶性黑色素瘤患者进行治疗，取得了乐观的结果。39例患者中有33例曾接受过化疗（达卡巴嗪和/或福莫司汀：31例，CDDP：6例），39例中有17例曾接受过IFNα-2a治疗。总体缓解率为54%，13%的患者实现了长达59周以上的完全缓解。中度至重度副作用在停用rIL-2后可逆，毒性在常规住院环境中可控。这些结果尤其令人鼓舞，因为它们出现在先前接受过治疗的患者中，这些患者通常反应较差，包括3例对顺铂或其他铂类复合物耐药的患者。问题仍然是该方案是否绕过了传统的耐药机制。
